NASDAQ:SNSE Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis $0.68 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.65▼$0.7050-Day Range$0.59▼$1.5052-Week Range$0.51▼$1.94Volume12,756 shsAverage Volume27,455 shsMarket Capitalization$16.96 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sensei Biotherapeutics alerts: Email Address Sensei Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside540.8% Upside$4.33 Price TargetShort InterestHealthy1.67% of Float Sold ShortDividend StrengthN/ASustainability-0.38Upright™ Environmental ScoreNews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.09) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector101st out of 936 stocksPharmaceutical Preparations Industry37th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingSensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSensei Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Sensei Biotherapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.67% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sensei Biotherapeutics has recently decreased by 2.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sensei Biotherapeutics is -0.38. Previous Next 3.3 News and Social Media Coverage News SentimentSensei Biotherapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.50% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.50% of the stock of Sensei Biotherapeutics is held by institutions.Read more about Sensei Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sensei Biotherapeutics are expected to decrease in the coming year, from ($1.09) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sensei Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Sensei Biotherapeutics Stock (NASDAQ:SNSE)Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Read More SNSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNSE Stock News HeadlinesJuly 24 at 5:09 AM | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 4.8%May 30, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 28, 2024 | seekingalpha.comSNSE Sensei Biotherapeutics, Inc.May 25, 2024 | markets.businessinsider.comBuy Rating on Sensei Biotherapeutics: Innovations and Promising Clinical DevelopmentsMay 24, 2024 | msn.comSensei stock plunges 46% in wake of Phase 1 dataMay 24, 2024 | investorplace.comWhy Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?May 23, 2024 | globenewswire.comSensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 14, 2024 | msn.comStephens & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Overweight RecommendationMay 13, 2024 | markets.businessinsider.comBuy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial StabilityMay 9, 2024 | investorplace.comSNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024May 9, 2024 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 24, 2024 | globenewswire.comSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingApril 9, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceApril 4, 2024 | uk.investing.comSensei Biotherapeutics CFO Erin Colgan to resignApril 4, 2024 | globenewswire.comSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentMarch 22, 2024 | globenewswire.comSensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumSee More Headlines Receive SNSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNSE CUSIPN/A CIK1829802 Webwww.senseibio.com Phone240-243-8000FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$4.33 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+540.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.67% Return on Assets-40.88% Debt Debt-to-Equity Ratio0.01 Current Ratio12.07 Quick Ratio12.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.26Miscellaneous Outstanding Shares25,080,000Free Float18,685,000Market Cap$16.96 million OptionableNot Optionable Beta0.03 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. John K. Celebi M.B.A. (Age 52)President, CEO & Director Comp: $882.28kDr. Edward Van der Horst Ph.D. (Age 50)Chief Scientific Officer Comp: $630.81kMs. Lora PikeVice President of Investor Relations & CommunicationsMr. Christopher W. Gerry J.D.Senior VP, General Counsel & SecretaryMs. Stephanie Krebs M.B.A. (Age 46)M.S., Chief Business Officer Dr. Aaron Weitzman FACPM.D., Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsTherapeuticsMDNASDAQ:TXMDExagenNASDAQ:XGNCytosorbentsNASDAQ:CTSOAnebulo PharmaceuticalsNASDAQ:ANEBHookipa PharmaNASDAQ:HOOKView All CompetitorsInsidersJohn CelebiBought 500 shares on 9/11/2023Total: $425.00 ($0.85/share)View All Insider Transactions SNSE Stock Analysis - Frequently Asked Questions How have SNSE shares performed this year? Sensei Biotherapeutics' stock was trading at $0.6920 at the beginning of the year. Since then, SNSE stock has decreased by 2.3% and is now trading at $0.6762. View the best growth stocks for 2024 here. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced its earnings results on Thursday, May, 9th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.03. When did Sensei Biotherapeutics IPO? Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. acted as the underwriters for the IPO. How do I buy shares of Sensei Biotherapeutics? Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNSE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.